Multiple myeloma is an extremely complex genomic disease that accounts for 1% of all cancers and 13% of all hematologic malignancies. Worldwide, approximately 86,000 new cases occur annually. Recently, clinical research in multiple myeloma has been very active, and various novel therapies are being investigated. This White Paper addresses several important components of this research, including biomarkers, imaging, and operational considerations.